Publication | Closed Access

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

MedicineReceptor Tyrosine KinasePathologyCell DeathDe Novo ResistanceNsclc PatientsSystems BiologyOncologyRadiation OncologyEgfr MutationCancer Growth